Monitor the sNDA submission for selinexor in myelofibrosis in August 2026 and any FDA feedback; a positive outcome could be a major catalyst. Also watch for announcements regarding financing or strategic alternatives, which could lead to dilution or a sale of the company.
Price Chart
Executive Summary
Karyopharm announced Phase 3 XPORT-EC-042 trial failure for selinexor in endometrial cancer (PFS p=0.0791, not significant), while simultaneously disclosing plans to submit an sNDA for selinexor in myelofibrosis in August 2026 under accelerated approval, though the FDA has requested further discussion on supporting data. The company is also exploring financing and strategic alternatives with Centerview Partners to extend its cash runway, signaling financial pressure.
Key Facts
- Phase 3 XPORT-EC-042 trial of selinexor in TP53 wild-type endometrial cancer failed to meet primary endpoint of PFS (HR=0.76, p=0.0791, not statistically significant)
- Company plans to submit sNDA for selinexor + ruxolitinib in myelofibrosis in August 2026 under accelerated approval pathway
- FDA provided written feedback that SVR35 qualifies as a surrogate endpoint but requires further discussion on data to support sNDA and conversion to traditional approval
- Company exploring financing transactions and strategic alternatives with Centerview Partners to extend cash runway; no assurance of any transaction
- Trial results do not affect ongoing trials of selinexor in other indications
Financial Impact
No financial figures provided in the filing; the failed trial removes a potential revenue stream, while the myelofibrosis sNDA represents a key pipeline catalyst. Cash runway concerns are highlighted by the strategic alternatives exploration.
Risk Factors
- FDA may not accept the sNDA or may require additional data, delaying or preventing accelerated approval
- Failed endometrial cancer trial reduces pipeline optionality and may impair investor confidence
- Company may need to raise capital on dilutive terms or fail to secure financing, increasing going-concern risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-326995 |
| Document: 0001193125-26-326995-index-headers.html | 0001193125-26-326995 |
| Document: 0001193125-26-326995-index.html | 0001193125-26-326995 |
| Document: 0001193125-26-326995.txt | 0001193125-26-326995 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $1.61 $1.88 | ▼ −16.77% | ▼ −16.99% | $0.8050 (+50.00%) |
Aug 31, 2026 4w ago | 8-K | $2.06 $1.72 | ▼ −16.50% | ▼ −16.36% | $0.8050 (−60.92%) |
Aug 13, 2026 7w ago | 8-K | $1.99 $1.82 | ▲ +8.54% | ▲ +6.58% | $0.8050 (+59.55%) |
Aug 10, 2026 7w ago | Press Release | $1.96 $1.81 | ▼ −7.65% | ▼ −7.61% | $0.8050 (−58.93%) |
Jul 31, 2026 9w ago | 8-K | $1.92 $2.12 | ▲ +10.42% | ▲ +6.91% | $0.8050 (−58.07%) |
Jul 17, 2026 10w ago | 8-K | $7.47 $7.41 | ▼ −0.80% | ▼ −0.38% | $0.8050 (−89.22%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▼ −25.63% | ▼ −24.01% | $0.8050 (+88.73%) |
May 15, 2026 19w ago | Insider Cluster | $7.14 $8.97 | ▲ +25.63% | ▲ +24.01% | $0.8050 (−88.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access